News | May 26, 2025
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
There was no observation related to data integrity reported
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Subscribe To Our Newsletter & Stay Updated
